Sign in
Not yet recruitingPhase 4

Effectiveness of An Influenza/COVID-19 Vaccine (mCombriax [mRNA-1083]) in Adults ≥ 65 Years

Key facts

Who runs it
Tor Biering-Sørensen
Where
Denmark and Spain3 sites in 2 countriesChoose a country to see its sites
Status
Not yet recruiting
Phase
Phase 4
People taking part
410,000 people, planned
Started
1 Sept 2026
Expected to end
30 Sept 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • mCombriax® (mRNA-1083)
  • Efluelda® (TIV-HD) and Spikevax® (mRNA-1273)
Record updated
27 August 2026

Who can take part

Age
65 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Age ≥65 years at the time of vaccination
  • Self-reported ability to understand written and spoken English or Danish (Denmark only) or Spanish or Galician (Spain only)
  • Informed consent form has been signed and dated

Who cannot take part

  • There are no specific exclusion criteria for this study

This trial has no sites in United States.

It has sites in 2 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this pragmatic randomized trials is to evaluate the comparative vaccine effectiveness (cVE) of mCombriax® (mRNA-1083) versus same day co-administration of the active comparators (i.e., high-dose influenza vaccine/Efluelda® and mRNA-1273/Spikevax®) among adults aged 65 years and older.

The 2 groups in the trial

  • mCombriax® (mRNA-1083)Treatment being tested

    An authorized mRNA-based multicomponent vaccine encoding antigens targeting both seasonal influenza and SARS-CoV-2 viruses.

  • Efluelda® (TIV-HD) and Spikevax® (mRNA-1273)Existing treatment, for comparison

    Same-day co-administration of an authorized high-dose trivalent influenza vaccine (TIV-HD; Efluelda®) and an authorized COVID-19 mRNA vaccine (Spikevax®, mRNA-1273)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 4, Pragmatic, Randomized Trial to Evaluate the Effectiveness of An Influenza/COVID-19 Vaccine (mCombriax [mRNA-1083]) in Adults ≥ 65 Years
Record updated
27 August 2026